This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Integrated DNA Technologies | |
|---|---|
| Name | Integrated DNA Technologies |
| Type | Private |
| Industry | Biotechnology |
| Founded | 1993 |
| Founder | Joseph Walder |
| Headquarters | Coralville, Iowa |
| Products | Oligonucleotides, synthetic genes, CRISPR reagents, pooled libraries |
| Services | DNA synthesis, oligo design, sequencing support, custom assays |
Integrated DNA Technologies is a private biotechnology company specializing in nucleic acid synthesis, genomics reagents, and molecular biology services. Founded in the early 1990s, the company supplies academic laboratories, pharmaceutical firms, and biotechnology startups with oligonucleotides, synthetic genes, and CRISPR tools. IDT products support research areas linked to genomics, diagnostics, and synthetic biology.
Integrated DNA Technologies was established in 1993 by Joseph Walder in Iowa City, Iowa with early commercial activity that paralleled developments at Genentech, Amgen, and Thermo Fisher Scientific in the 1990s. The firm's growth occurred alongside landmark events such as the Human Genome Project and regulatory milestones in the U.S. Food and Drug Administration's oversight of molecular diagnostics. Expansion phases mirrored consolidation trends exemplified by mergers like Roche's acquisitions and strategic moves by Illumina and Agilent Technologies. IDT opened manufacturing and distribution centers that connected to logistics hubs including Minneapolis–Saint Paul International Airport and ports such as Port of Los Angeles to serve collaborators in Cambridge, Massachusetts, San Francisco, Boston, and international sites across Europe and Asia.
IDT's product lines include custom oligonucleotides, long-read gene constructs, next-generation sequencing (NGS) library reagents, and CRISPR-Cas systems comparable in market focus to offerings from New England Biolabs and Promega. Customers use IDT supplies in workflows involving instruments from Illumina, Pacific Biosciences, and Oxford Nanopore Technologies. Service offerings encompass custom DNA synthesis, pooled-guide libraries for functional screens, assay design portals that integrate with databases such as GenBank and Ensembl, and support for regulatory submissions to bodies like the European Medicines Agency. IDT markets diagnostic panels used in laboratory settings similar to tests developed by Roche Diagnostics and Abbott Laboratories.
Research initiatives at IDT have aligned with advances in synthetic biology seen in groups at MIT, Harvard University, and Stanford University. The company has developed improvements in phosphoramidite chemistry and high-throughput synthesis platforms paralleling innovations at Merck Group research units. IDT engages in method development for guide RNA design for CRISPR applications informed by studies from laboratories such as those of Jennifer Doudna and Emmanuelle Charpentier. Collaborative research ties connect to projects at Broad Institute and consortiums like the 1000 Genomes Project and efforts coordinated by National Institutes of Health institutes. IDT-supported protocols have been cited in preprints on servers like bioRxiv and in peer-reviewed journals including Nature and Science.
Manufacturing operations use automated synthesizers and quality control processes comparable to standards at Sigma-Aldrich and Thermo Fisher Scientific quality systems. IDT employs analytical instrumentation from vendors including Agilent Technologies for liquid chromatography, PerkinElmer for spectroscopy, and Thermo Fisher Scientific for mass spectrometry. Quality frameworks reference guidelines promulgated by regulatory agencies such as the U.S. Food and Drug Administration and accreditation organizations like College of American Pathologists. Supply chain resilience strategies reflect lessons from disruptions at multinational firms including 3M and logistics planning used by FedEx and DHL.
IDT operates as a privately held entity with executive leadership interacting with investors and partners in markets dominated by conglomerates like Bayer and Johnson & Johnson. Corporate functions encompass research and development, global sales teams operating in regions including Europe, Asia-Pacific, and the Americas, and legal departments managing intellectual property portfolios similar to practices at Genentech and Amgen. Financial planning and procurement align with industry standards manifested at companies such as Pfizer and GlaxoSmithKline. IDT's human resources and talent pipelines recruit from universities including University of Iowa, University of California, Berkeley, and Johns Hopkins University.
IDT has partnered with academic institutions like University of Texas Southwestern Medical Center and commercial partners that include sequencing firms and reagent suppliers analogous to collaborations between Illumina and academic consortia. Projects have involved public health agencies such as Centers for Disease Control and Prevention and international research networks like World Health Organization surveillance programs. Industrial alliances echo partnerships seen among Roche and biotech startups in translational initiatives at hubs such as Biotech Bay Area and Cambridge Biomedical Campus.
Ethical debates surrounding synthetic DNA and gene editing technologies involve stakeholders including bioethicists at The Hastings Center and policy forums such as the National Academies of Sciences, Engineering, and Medicine. Controversies mirror public discussion prompted by high-profile incidents in gene synthesis oversight and dual-use research exemplified by cases discussed at Duke University and in reports by National Science Advisory Board for Biosecurity. Regulatory scrutiny and community standards involve interactions with legislative bodies such as the United States Congress and oversight by professional societies including the American Society for Microbiology.
Category:Biotechnology companies